Brief: Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection
13/03/2025 14:07
March 13 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY ENROLLS FIRST PATIENT IN PHASE 3 ECLIPSE REGISTRATIONAL PROGRAM FOR CHRONIC HEPATITIS DELTA Source text: ID:nBw7x28pKa Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO